Thesis

EXEL's "patent cliff" narrative is materially de-risked. Two trial wins, two settlements, and a declined IPR push generic CABOMETYX entry to 2030—not 2026-2027 as bears price in. Meanwhile, zanzalintinib (PDUFA Dec 3, 2026) positions the company to transition from single-product to dual-product engine before the patent shield expires.

At 10× forward P/E with 17% product revenue growth and 50% EPS growth, the market is pricing the bear case. If the CAFC affirms the 2030 date AND zanzalintinib gets approved, significant asymmetry exists.

The Patent Cliff That Isn't

Market narrative: Composition of matter patent expires August 2026 → generic flood imminent.

Reality from 10-K litigation record:

MSN I (Composition of Matter): UPHELD

• Delaware District Court rejected MSN's invalidity challenge to the '473 patent (composition of matter)
• Judgment entered: MSN cannot get FDA approval before August 14, 2026
• This is settled law at trial level

MSN II (Later Patents): UPHELD THROUGH 2030

• October 2024 ruling: Delaware District Court rejected MSN's invalidity challenges to ALL asserted later patents ('439, '440, '015)
• MSN's ANDA effective date: No earlier than January 15, 2030
• MSN appealed to CAFC (briefing completed Aug 2025), but trial record is clean—they lost on every patent
• Consolidated trial Nov 2, 2026 addresses MSN challenge to '039 patent (expires 2032) plus Azurity challenge

Settlements Suggest Patent Thicket Is Holding

• Biocon: Settled July 2025 (terms undisclosed)
• Sun: Settled December 2025 (terms undisclosed)
• Settlements typically = negotiated entry dates, not at-risk launches

USPTO Declined IPR on Newest Patents

• Azurity's IPR challenge to '349 and '039 patents (2032 expiry) declined by USPTO
• Patent Office wouldn't even institute review—strong signal these patents are robust

Net assessment: Generic entry timeline is almost certainly 2030+, not 2026-2027. The only remaining risk is CAFC reversing the trial court (unlikely given clean record). Even if CAFC reverses, composition of matter holds through Aug 2026 regardless.

Two settlements, two trial wins, declined IPR → this patent thicket is holding.

Zanzalintinib: The Succession Plan

NDA submitted Dec 2025, FDA accepted with standard review:

• PDUFA target: December 3, 2026 (10 months)
• Indication: Previously treated metastatic colorectal cancer (non-MSI-H/dMMR)
• Trial data: STELLAR-303 phase 3

STELLAR-303 Results (ITT Population):

• 20% reduction in risk of death vs regorafenib
• Hazard ratio: 0.80 (95% CI: 0.69-0.93)
• p = 0.0045 (statistically significant on primary endpoint)
• Published in The Lancet, presented at ESMO 2025

Dual primary endpoint (OS in patients without liver mets):

• Interim analysis: 15.9 vs 12.8 months (HR 0.79, p=0.0875)
• Trending but not stat sig yet
• Final analysis expected mid-2026

Market size:

• CRC is 3rd most common cancer: ≈159K new US cases/yr, ≈55K deaths
• Metastatic stage has 15% five-year survival rate
• 40-52% of metastatic CRC cases exhibit RAS mutation

Additional Catalysts:

• STELLAR-304 (nccRCC + nivolumab): Top-line results expected mid-2026
• STELLAR-311 (NET): Enrolling
• Merck collaboration: 3 RCC trials evaluating zanzalintinib + belzutifan vs cabozantinib in 1L RCC
  • Merck funding one phase 3, EXEL retains all global commercial rights
  • Merck studying zanzan vs cabo in their own trials = legitimate cabo successor signal

Financials: Cash Cow Still Producing

FY2025 Results (vs FY2024):

Revenue drivers:

• 16% unit volume increase (combo with nivolumab driving longer duration of therapy + NET launch)
• Discounts/allowances growing faster than gross revenue (25% vs 20%)—340B headwind
• Collaboration revenue down 45% ($14.3M vs $169.3M)—milestone timing issue

Company guides: Continued product revenue growth in FY2026

Capital Allocation: Buying Back Stock Aggressively

Buyback activity:

• $1.16B repurchased in FY2025 (30.2M shares, ≈10% of shares outstanding)
• $590M remaining under October 2025 SRP (through Dec 2026)
• At current ≈$43, that's another ≈5% of shares outstanding

Restructuring:

• Two corporate restructurings (2024 Plan + 2025 Plan)
• Workforce down 6.1% to 1,077 employees
• Despite cuts, guiding for increased R&D and SG&A in FY2026 (zanzalintinib launch prep + pipeline trials)

Insider activity:

• Director David Johnson purchased $1.19M in stock at market in November 2025
• Board-level insider buying at $43 = confidence signal

Interpretation: Management buying back stock aggressively while simultaneously investing heavily in zanzalintinib and cutting non-essential overhead. Rational capital allocation for a company about to face a patent cliff—UNLESS management believes the cliff is pushed to 2030.

Market Data: Mispricing vs Litigation Reality

Valuation:

• Forward P/E: 10.0× (trailing P/E: 18.1×)
• 17% product revenue growth, 50% EPS growth
• For a growing biotech with major catalyst 10 months out, this is cheap—IF patent cliff is 2030

Positioning:

• Short interest: 13.3% of float, 10.3 days to cover (elevated)
• P/C ratio (open interest): 0.38 (bullish skew)
• IV: 75.2% (107th percentile vs 52-week range)—market pricing binary risk

Momentum:

• 1-year: +28.3% (moderate, not overextended)
• RSI: 38.9 (approaching oversold)
• Recent earnings: 4/4 beats (+16-40% surprise)

Analyst consensus:

• Mean target: $46.39 (+8%)
• Range: $30-60
• 9 Buy/Strong Buy, 9 Hold, 1 Strong Sell
• Street not aggressive here

Interpretation: Shorts are betting on imminent generic entry. If CAFC affirms 2030 date + STELLAR-304 hits + zanzalintinib approved, short squeeze setup is real.

IRA Pricing Risk: Manageable Near-Term

Small biotech manufacturer exception:

• Exempt from Medicare price negotiation through 2028
• Lower MFP floor in 2029-2030
• Company qualified for small biotech exception through 2027, intends to apply annually through 2030

Part D Manufacturer Discount Program:

• "Specified small manufacturer" designation = phase-in of increased Part D discounts from 2025-2031
• Discounts/allowances already growing 25% (vs 20% gross revenue growth)—340B program is main driver

Current administration:

• Exploring MFN pricing and potential pharmaceutical tariffs
• CMS announced pilot program for Medicaid
• Full scope, timing, and impact uncertain

Timeline: Gradual headwind, not cliff. If CABOMETYX gets selected for negotiation in 2029+ (single-source drug), revenue impact could be 25-60% on Medicare volume. But if zanzalintinib is approved and ramping by then, it becomes the replacement revenue source.

Catalysts Timeline (2026)

Competitive Landscape (CRC)

Transcript search confirms ABBV (cMet ADC), PFE (4404 combo), JNJ (Ribrovant), INCY (TGF-beta bispecific) all developing CRC programs. But these are earlier stage.

Zanzalintinib is furthest along:

• NDA filed
• Stat sig OS data (HR 0.80, p=0.0045)
• Standard review = 10-month timeline

First-mover advantage in refractory CRC is real—these patients are dying and will take what's available. By the time competitive programs read out (2027-2028), zanzalintinib will have 1-2 years of market presence.

Bear Case

1. CAFC reverses trial court: MSN wins on appeal, invalidates '439/'440/'015 patents → generic entry 2027-2028 instead of 2030

   • Probability: Low (clean trial record, MSN lost on every patent)
   • Impact: High (3 years of lost exclusivity)

2. Zanzalintinib not approved: FDA finds safety/efficacy issues despite stat sig OS data

   • Probability: Low (stat sig primary endpoint, standard review suggests no major concerns)
   • Impact: High (no successor product to CABOMETYX)

3. Zanzalintinib approved but sales disappoint: Market penetration slower than expected, pricing pressure, formulary access issues

   • Probability: Medium (launch execution risk always exists)
   • Impact: Medium (still have CABOMETYX cash flow through 2030)

4. IRA pricing hits harder/faster than expected: CMS selects CABOMETYX for negotiation earlier, 340B expansion accelerates

   • Probability: Medium (policy risk is real)
   • Impact: Medium-High (25-60% revenue haircut on Medicare volume)

Bull Case

1. Patent thicket holds through 2030: CAFC affirms trial court, no generic entry until Jan 15, 2030

   • Probability: High (two trial wins, two settlements, declined IPR)
   • Impact: High (3+ extra years of CABOMETYX exclusivity)

2. Zanzalintinib approved Dec 2026: FDA approves on PDUFA date, launch begins 1Q2027

   • Probability: High (stat sig OS data, standard review)
   • Impact: High (second major product, diversifies revenue)

3. STELLAR-304 hits mid-2026: nccRCC data positive, broadens zanzalintinib label to second indication

   • Probability: Medium-High (nccRCC is underserved, combo with nivolumab has strong rationale)
   • Impact: High (accelerates zanzalintinib ramp, validates platform)

4. Merck collaboration validates zanzalintinib: Phase 3 trials show zanzan competitive with cabo in 1L RCC

   • Probability: Medium (Merck wouldn't run head-to-head trials unless they saw potential)
   • Impact: High (cabo franchise extends via successor molecule)

Synthesis

EXEL is a company in transition.

The thesis boils down to:

1. CABOMETYX cash cow ($2.1B revenue, growing 17%) funds everything—but faces patent cliff
2. Litigation record suggests cliff is 2030, not 2026-2027 (2 trial wins, 2 settlements, declined IPR)
3. Zanzalintinib is the designated successor—PDUFA Dec 3, 2026 for CRC, with broad development program
4. Valuation at 10× forward P/E seems cheap for a growing biotech—UNLESS you price in 2027 generic entry

The key question: Can the later patents (2030-2033) hold off generics long enough for zanzalintinib to ramp?

If yes: EXEL has a multi-year growth runway with a second major product launching into a huge market (CRC). Double-product engine by 2027-2028.

If no: Generic CABOMETYX arrives 2027-2028, zanzalintinib launch can't offset revenue decline fast enough.

Market appears to be pricing mostly the bear scenario at 10× forward P/E. If patent litigation resolves favorably (CAFC affirms) AND zanzalintinib gets approved, significant upside exists.

Director insider buying at $43 level supports this view: Board member putting $1.19M of personal capital at current prices suggests confidence in the litigation outcome + zanzalintinib approval.

13.3% short interest with 10.3 days to cover creates squeeze potential if:

• STELLAR-304 hits mid-2026
• Zanzalintinib approved Dec 2026
• CAFC affirms 2030 generic entry date

Epistemic State: Doorway

Two plausible scenarios with different probabilities:

60% Bull: Patent thicket holds 2-3 years, zanzalintinib approved late 2026, double product engine by 2027-2028

• CAFC affirms trial court (high probability given clean record)
• Zanzalintinib approval (high probability given stat sig OS)
• STELLAR-304 success (medium-high probability)
• Target: $55-65 (30-50% upside)

40% Bear: Courts invalidate key patents OR zanzalintinib delayed/rejected, generic CABOMETYX by 2027-2028, single-product revenue decline

• CAFC reverses (low probability but high impact)
• OR zanzalintinib approval delayed/CRL (low probability but high impact)
• Target: $30-35 (30% downside)

Sizing implication: Asymmetric setup favors upside. 60/40 probability distribution with 40% upside / 25% downside suggests positive expected value. But size for surviving the 40% scenario.

Catalyst timeline matters: Multiple binary events in next 10 months. Pattern collapses by end of 2026.

What the Street Misses

Analyst consensus at $46 (+8%) suggests the Street is modeling:

• Generic entry 2027-2028 (ignoring litigation wins)
• OR discounting zanzalintinib approval probability
• OR both

The 10-K litigation record tells a different story:

• MSN lost at trial level on ALL patents except '349 (non-infringement, but patent valid)
• Two settlements (Biocon July 2025, Sun Dec 2025)
• USPTO declined IPR on newest patents
• Clean trial record makes CAFC reversal unlikely

If the market is wrong about the patent timeline, the mispricing is material.

At 10× forward P/E for a 17% grower with $1.66B cash, $590M buyback remaining, and a major catalyst 10 months out, EXEL screens cheap—if you believe 2030 over 2027.

The bet: Patent thicket holds + zanzalintinib approved = multi-year runway before genericization.